Table 1.
Baseline demographics and clinical characteristics by trial and by baseline CRP subgroup.
| STEP 1 |
STEP 2 |
STEP 3 |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| <1 mg/L | 1–3 mg/L | >3 mg/L | <1 mg/L | 1–3 mg/L | >3 mg/L | <1 mg/L | 1–3 mg/L | >3 mg/L | |
| Participants, n | 223 | 574 | 1155 | 168 | 361 | 674 | 50 | 148 | 405 |
| CRP, geometric mean (CV), mg/L | 0.6 (42.9) | 1.9 (31.3) | 7.9 (70.5) | 0.6 (50.3) | 1.8 (32.1) | 7.5 (68.1) | 0.6 (48.1) | 1.8 (34.2) | 7.9 (70.4) |
| Age, years | 48 (13) | 49 (13) | 45 (13) | 58 (10) | 57 (10) | 54 (11) | 50 (13) | 48 (13) | 45 (12) |
| Female sex, n | 104 (46.6%) | 385 (67.1%) | 956 (82.8%) | 48 (28.6%) | 147 (40.7%) | 417 (61.9%) | 35 (70.0%) | 105 (70.9%) | 349 (86.2%) |
| Race, n | |||||||||
| White | 135 (60.5%) | 433 (75.4%) | 894 (77.6%) | 86 (51.2%) | 247 (68.4%) | 414 (61.4%) | 39 (78.0%) | 111 (75.0%) | 310 (76.5%) |
| Asian | 69 (30.9%) | 73 (12.7%) | 119 (10.3%) | 73 (43.5%) | 85 (23.5%) | 159 (23.6%) | 1 (2.0%) | 4 (2.7%) | 6 (1.5%) |
| Black/African American | 12 (5.4%) | 21 (3.7%) | 77 (6.7%) | 5 (3.0%) | 17 (4.7%) | 78 (11.6%) | 7 (14.0%) | 27 (18.2%) | 80 (19.8%) |
| Othera | 7 (3.1%) | 47 (8.2%) | 63 (5.5%) | 4 (2.4%) | 12 (3.3%) | 23 (3.4%) | 3 (6.0%) | 6 (4.1%) | 9 (2.2%) |
| Ethnicity, n | |||||||||
| Not Hispanic/Latino | 202 (90.6%) | 500 (87.1%) | 961 (83.2%) | 155 (92.3%) | 309 (85.6%) | 585 (86.8%) | 43 (86.0%) | 120 (81.1%) | 319 (78.8%) |
| Hispanic/Latino | 18 (8.1%) | 51 (8.9%) | 164 (14.2%) | 13 (7.7%) | 52 (14.4%) | 89 (13.2%) | 7 (14.0%) | 28 (18.9%) | 86 (21.2%) |
| Otherb | 3 (1.3%) | 23 (4.0%) | 30 (2.6%) | 0 | 0 | 0 | 0 | 0 | 0 |
| Bodyweight, kg | 97.2 (18.7) | 100.0 (18.3) | 109.6 (23.1) | 92.6 (16.5) | 96.1 (18.3) | 103.6 (23.4) | 93.8 (15.6) | 101.8 (19.1) | 108.9 (24.1) |
| BMI, kg/m2 | 33.8 (5.1) | 35.7 (5.1) | 39.7 (7.0) | 32.0 (4.1) | 33.8 (4.9) | 37.6 (6.7) | 33.0 (3.6) | 35.9 (4.9) | 39.5 (7.1) |
| Waist circumference, cm | 108.4 (12.8) | 111.5 (12.8) | 117.4 (15.2) | 108.1 (11.0) | 111.3 (11.9) | 118.0 (14.8) | 103.7 (11.3) | 110.5 (12.9) | 115.1 (16.1) |
| HbA1c, % | 5.7 (0.3) | 5.7 (0.3) | 5.7 (0.3) | 7.9 (0.8) | 8.1 (0.8) | 8.2 (0.8) | 5.7 (0.3) | 5.7 (0.3) | 5.8 (0.3) |
| Statin/lipid-lowering agent users, n | 42 (18.8%) | 134 (23.3%) | 128 (11.1%) | 113 (67.3%) | 232 (64.3%) | 311 (46.1%) | 11 (22.0%) | 32 (21.6%) | 46 (11.4%) |
Data are mean (SD), unless otherwise stated, for all trial participants with a baseline CRP assessment.
BMI, body mass index; CRP, C-reactive protein; CV, coefficient of variation; HbA1c, glycated haemoglobin; SD, standard deviation.
a
American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, not applicable (data on race are not collected for France), or other.
b
Not applicable (data on ethnicity are not collected for France) or unknown.